Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers

Sperner‐Unterweger, Barbara; Neurauter, Gabriele; Klieber, Martin; Kurz, Katharina; Meraner, Verena; Zeimet, Alain G.; Fuchs, Dietmar

doi:10.1016/j.imbio.2010.07.010

Cited by 49 publications

(47 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tryptophan and LPCs have been suspected to participate in cancer progression, and 2-piperidinone might be a novel biomarker for EOC [73]. Accelerated L-tryptophan degradation has been observed in the blood of EOC patients when compared to the healthy controls [74]. A similar phenomenon has been observed in other malignant tumors.…”

Section: Ovarian Cancermentioning

confidence: 55%

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Zhao

Cheng

Vaziri

et al. 2014

Clinical Biochemistry

118

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oObjectives: Metabonomics is a powerful and promising analytic tool that allows assessment of global lowmolecular-weight metabolites in biological systems. It has a great potential for identifying useful biomarkers for early diagnosis, prognosis and assessment of therapeutic interventions in clinical practice. The aim of this review is to provide a brief summary of the recent advances in UPLC-based metabonomic approach for biomarker discovery in a variety of diseases, and to discuss their significance in clinical chemistry.Design and methods: All the available information on UPLC-based metabonomic applications for discovering biomarkers of diseases were collected via a library and electronic search (using Web of Science, Pubmed, ScienceDirect, Springer, Google Scholar, etc.).Results: Metabonomics has been used in clinical chemistry to identify and evaluate potential biomarkers and therapeutic targets in various diseases affecting the liver (hepatocarcinoma and liver cirrhosis), lung (lung cancer and pneumonia), gastrointestinal tract (colorectal cancer) and urogenital tract (prostate cancer, ovarian cancer and chronic kidney disease), as well as metabolic diseases (diabetes) and neuropsychiatric disorders (Alzheimer's disease and schizophrenia), etc.Conclusions: The information provided highlights the potential value of determination of endogenous lowmolecular-weight metabolites and the advantages and potential drawbacks of the application of UPLC-based metabonomics in clinical setting.

show abstract

Section: Ovarian Cancermentioning

confidence: 55%

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Zhao

Cheng

Vaziri

et al. 2014

Clinical Biochemistry

118

View full text Add to dashboard Cite

show abstract

“…Also, the tryptophan serum level and the tryptophan-to-kynurenin ratio have been found to be significantly lower in patients with ovarian carcinoma compared with healthy women. This level correlated with different serum immune activation markers (40). Together, these results point out that the IDO expressed in tumor tissue can be enzymatically active, but no mechanistic link has been established as a causative factor.…”

Section: Discussionmentioning

confidence: 85%

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

Godin-Ethier

Hanafi²,

Piccirillo³

et al. 2011

Clinical Cancer Research

348

249

View full text Add to dashboard Cite

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme with immune-regulating activities in many contexts, such as fetal protection, allograft protection, and cancer progression. Clinical trials are currently evaluating IDO inhibition with 1-methyltryptophan in cancer immunotherapy. However, the exact role of tryptophan catabolism by IDO in human cancers remains poorly understood. Here, we review several studies that correlate IDO expression in human cancer samples and tumor-draining lymph nodes, with relevant clinical or immunologic parameters. IDO expression in various histologic cancer types seems to decrease tumor infiltration of immune cells and to increase the proportion of regulatory T lymphocytes in the infiltrate. The impact of IDO on different immune cell infiltration leads to the conclusion that IDO negatively regulates the recruitment of antitumor immune cells. In addition, increased IDO expression correlates with diverse tumor progression parameters and shorter patient survival. In summary, in the vast majority of the reported studies, IDO expression is correlated with a less favorable prognosis. As we may see results from the first clinical trials with 1-methyltryptophan in years to come, this review brings together IDO studies from human studies and aims to help appreciate outcomes from current and future trials. Consequently, IDO inhibition seems a promising approach for cancer immunotherapy.

show abstract

“…It has been reported that relative to healthy controls, serum Trp levels are significantly lower in several types of cancer, such as colorectal cancer (32) and ovarian carcinoma (33), in addition to ATL (24). This might be due to accelerated Trp catabolism mediated by the IDO produced by tumor cells and/or cells of the tumor microenvironment.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma

Awata

Ishida

Maeda

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Indoleamine 2,3-dioxygenase 1 (IDO1: IDO), an enzyme catabolizing tryptophan (Trp) into the kynurenine (Kyn) pathway, is increasingly being recognized as an important microenvironmental factor suppressing antitumor immune responses. The purpose of the present study was to determine the prognostic significance of Trp catabolism in adult T-cell leukemia/lymphoma (ATL).Experimental Design: We quantified serum Trp and Kyn in 96 ATL patients, 38 human T-cell lymphotropic virus type-1 asymptomatic carriers (HTLV-1 ACs), and 40 healthy adult volunteer controls. The relationships between various clinical parameters including overall survival were analyzed. IDO expression was evaluated in the affected lymph nodes of ATL patients.Results: Serum Kyn concentrations and Kyn/Trp ratios were significantly higher in HTLV-1 ACs than healthy controls. Both increased significantly with progression from HTLV-1 AC to ATL. However, there were no significant differences in the serum Trp concentrations between ATL patients, HTLV-1 ACs, and controls. IDO was possibly produced by ATL and/or cells of the microenvironment. Multivariate analyses demonstrated that a high serum Kyn/Trp ratio and high Kyn level, but not a high Trp level, were significantly independent detrimental prognostic factors in ATL, as well as in that subset of patients with aggressive variant ATL.Conclusions: Quantification of serum Kyn and Trp is useful for predicting prognosis of an individual ATL patient. Furthermore, ATL, especially in patients with a high serum Kyn/ Trp ratio, is an appropriate disease for testing novel cancer immunotherapies targeting IDO.

show abstract

Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers

Cited by 49 publications

References 45 publications

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma

Contact Info

Product

Resources

About